Open access
Open access
Powered by Google Translator Translator

Pharmacology/Pharmaceutical Industry

M-A: No difference in outcomes with Beta-lactam monotherapy vs. combination therapy for bloodstream infections or pneumonia due to P. aeruginosa.

21 Jan, 2022 | 09:37h | UTC

Beta-lactam monotherapy or combination therapy for bloodstream infections or pneumonia due to P. aeruginosa: a meta-analysis – International Journal of Antimicrobial Agents (link to abstract – $ for full-text)

 

M-A: In patients with acute coronary syndrome, a guided approach (i.e., platelet function or genetic testing) to P2Y12 inhibiting therapy may reduce major adverse cardiovascular events without increased risk of bleeding.

21 Jan, 2022 | 09:33h | UTC

Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials – European Heart Journal (link to abstract – $ for full-text)

Commentary: Another Win for Guided P2Y12 Therapy in ACS: Meta-analysis – TCTMD

 

Commentary on Twitter

 

Booster longevity: Data reveals how long a third shot protects.

20 Jan, 2022 | 09:33h | UTC

Booster longevity: Data reveals how long a third shot protects – NPR

Original Report: SARS-CoV-2 variants of concern and variants under investigation in England – U.K. Health Security Agency

 

A populational-based retrospective cohort study in Qatar showed a reduced risk of Covid-19 breakthrough infections with the Moderna vs. the Pfizer–BioNTech vaccine.

20 Jan, 2022 | 09:30h | UTC

Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar – New England Journal of Medicine

 

Commentary on Twitter

 

RCT: Lidocaine spray may reduce pain during radial arterial puncture.

21 Jan, 2022 | 09:19h | UTC

Effectiveness of lidocaine spray on radial arterial puncture pain: A randomized double-blind placebo controlled trial – The American Journal of Emergency Medicine (link to abstract – $ for full-text)

 

Short Review: Fluvoxamine for symptomatic outpatients with COVID-19.

20 Jan, 2022 | 09:25h | UTC

Fluvoxamine for symptomatic outpatients with COVID-19 – Canadian Medical Association Journal

Related:

Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.

Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.

RCT: Early treatment with fluvoxamine reduced the risk of emergency care and hospitalization among patients with COVID-19.

[Preprint] RCT: Fluvoxamine reduced the risk for ER visits and hospitalization among patients with Covid-19.

Opinion | Could this be our first effective, inexpensive, widely available outpatient treatment for COVID-19? (It’s fluvoxamine).

Preliminary study shows fluvoxamine may reduce clinical deterioration in outpatients with symptomatic COVID-19

 

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.

20 Jan, 2022 | 09:17h | UTC

Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis – The Lancet

News Release: An estimated 1.2 million people died in 2019 from antibiotic-resistant bacterial infections, more deaths than HIV/AIDS or malaria – The Lancet

Editorial: Antimicrobial resistance: time to repurpose the Global Fund – The Lancet

Commentary: Antimicrobial resistance now a leading cause of death worldwide, study finds – The Guardian

 

Commentary on Twitter

 

RCT: Among patients with recurrent Clostridioides difficile infection, the use of SER-109, an oral microbiome therapy, reduced recurrence rate compared to placebo (12% vs. 40%).

20 Jan, 2022 | 09:11h | UTC

SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection – New England Journal of Medicine (link to abstract – $ for full-text)

 

Meta-analysis of randomized controlled trials: Drug treatment for panic disorder with or without agoraphobia.

20 Jan, 2022 | 09:06h | UTC

Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials – The BMJ

 

Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events, researchers find.

19 Jan, 2022 | 08:53h | UTC

News Release: Placebo effect accounts for more than two-thirds of COVID-19 vaccine adverse events, researchers find – Beth Israel Deaconess Medical Center

Original Study: Frequency of Adverse Events in the Placebo Arms of COVID-19 Vaccine Trials: A Systematic Review and Meta-analysis – JAMA Network Open

Commentary: ‘Nocebo effect’: two-thirds of Covid jab reactions not caused by vaccine, study suggests – The Guardian

 

RCT: In critically ill adults, using a balanced multielectrolyte solution did not lower the risk of death or acute kidney injury compared to standard saline.

19 Jan, 2022 | 08:41h | UTC

Balanced Multielectrolyte Solution versus Saline in Critically Ill Adults – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Australian study set to guide the treatment of critically ill patients worldwide – George Institute for Global Health

Related:

BaSICS RCT: Among critically ill patients requiring fluid therapy, treatment with a balanced solution did not lead to reduced mortality compared to a 0.9% saline solution.

BaSICS RCT: Among critically ill patients requiring fluid therapy, there was no difference in mortality with slower (333 mL/h) vs. faster (999 mL/h) intravenous fluid bolus rates.

Cochrane Review: Buffered Solutions Do Not Improve Mortality in Critically Ill Adults and Children Compared to 0,9% Saline

 

Commentary on Twitter

https://twitter.com/NEJM/status/1483540959518281730

 

RCT: In children with community-acquired pneumonia, outpatient antibiotic therapy for 5 days resulted in similar clinical response rates compared to a standard 10-day strategy.

19 Jan, 2022 | 08:39h | UTC

Short- vs Standard-Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children: The SCOUT-CAP Randomized Clinical Trial – JAMA Pediatrics (free for a limited period)

Commentaries:

Trial finds 5 days of antibiotics superior to 10 for kids with pneumonia – CIDRAP

Shorter antibiotics treatment is better for young children with outpatient pneumonia – Vanderbilt University Medical Center

Related:

ACP Guidance: Appropriate Use of Short-Course Antibiotics in Common Infections

RCT: 5 days of high-dose amoxicillin therapy noninferior to 10 days for the treatment of pediatric community-acquired pneumonia

RCT: Among children with community-acquired pneumonia discharged within 48 hours from the ED or hospital, lower-dose outpatient oral amoxicillin was noninferior to a higher dose, and a 3-day duration course was noninferior to 7 days.

Treatment of urinary tract infections in infants <2 Months: A Living Systematic Review – short and long duration of parenteral antibiotics were associated with a similar risk of UTI recurrence.

RCT: 7 days of antibiotic therapy as good as 14 days for afebrile men with urinary tract infection.

Randomized Trial: Seven vs. Fourteen Days of Antibiotic Therapy for Uncomplicated Gram-negative Bacteremia

Meta-Analysis: Efficacy of Short-Course Antibiotic Treatments for Community-Acquired Pneumonia

 

Clinical practice guidelines for therapeutic drug monitoring of teicoplanin.

19 Jan, 2022 | 08:27h | UTC

Clinical practice guidelines for therapeutic drug monitoring of teicoplanin: a consensus review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring – Journal of Antimicrobial Chemotherapy

 

Dermatologic immune-related adverse events: the toxicity spectrum and recommendations for management.

19 Jan, 2022 | 08:15h | UTC

Dermatologic immune-related adverse events: The toxicity spectrum and recommendations for management – International Journal of Women’s Dermatology

Related: Management of Dermatologic Adverse Events from Cancer Therapies

 

M-A: Evaluation of interventions to reduce opioid prescribing for patients discharged from the emergency department.

19 Jan, 2022 | 08:13h | UTC

Evaluation of Interventions to Reduce Opioid Prescribing for Patients Discharged From the Emergency Department: A Systematic Review and Meta-analysis – JAMA Network Open

Invited commentary: Optimizing Opioid Prescriptions for Patients in the Emergency Department—How Much Is Almost Never? – JAMA Network Open

 

Commentary on Twitter

 

[Not published yet] Study in Israel finds fourth COVID booster has limited efficacy.

18 Jan, 2022 | 09:59h | UTC

Israel Finds Fourth COVID Booster is Ineffective, While Hospitalised Omicron Patients Fare Much Better Than Delta Patients – Health Policy Watch

See also:

Israeli trial, world’s first, finds 4th dose ‘not good enough’ against Omicron – The Times of Israel

Israel study: 4th vaccine shows limited results with omicron – MedicalXpress

 

COVID-19 updated evidence: a Cochrane round-up.

18 Jan, 2022 | 09:53h | UTC

COVID-19 evidence: a Cochrane round-up – Cochrane Library

 

Case series of Thrombosis with Thrombocytopenia Syndrome after Covid-19 vaccination in the US.

18 Jan, 2022 | 09:41h | UTC

Case Series of Thrombosis With Thrombocytopenia Syndrome After COVID-19 Vaccination—United States, December 2020 to August 2021 – Annals of Internal Medicine

Editorial: The Epidemiology of Thrombosis With Thrombocytopenia Syndrome: Analogies With Heparin-Induced Thrombocytopenia – Annals of Internal Medicine

 

Association of hormonal contraceptive use with adverse health outcomes: an umbrella review of meta-analyses of randomized clinical trials and cohort studies.

18 Jan, 2022 | 09:29h | UTC

Association of Hormonal Contraceptive Use With Adverse Health Outcomes: An Umbrella Review of Meta-analyses of Randomized Clinical Trials and Cohort Studies – JAMA Network Open

 

WHO recommends two new drugs (Baricitinib and Sotrovimab) to treat COVID-19.

17 Jan, 2022 | 00:48h | UTC

News release: WHO recommends two new drugs to treat COVID-19 – World Health Organization

Infographic with the updated recommendations: A living WHO guideline on drugs for covid-19 – The BMJ

Commentaries:

WHO Recommends Two New COVID-19 Treatments – Cost and Availability Likely Barriers – Health Policy Watch

Expert reaction to WHO recommending two drugs, sotrovimab and baricitinib, to treat patients with COVID-19 – Science Media Centre

 

Commentary on Twitter (thread – click for more)

 

Viewpoint: COVID-19 therapeutics for nonhospitalized patients.

17 Jan, 2022 | 00:31h | UTC

COVID-19 Therapeutics for Nonhospitalized Patients – JAMA

Editorial: Realizing the Potential of Anti–SARS-CoV-2 Monoclonal Antibodies for COVID-19 Management – JAMA

 

RCT: Oral Vitamin D supplementation (60.000 IU per month) did not reduce mortality in patients 60 years or older (unscreened individuals in Australia, many without insufficiency, average 30ng/mL). Exploratory analyses pointed towards an increased risk of death from cancer.

16 Jan, 2022 | 23:13h | UTC

The D-Health Trial: a randomised controlled trial of the effect of vitamin D on mortality – The Lancet Diabetes & Endocrinology (link to abstract – $ for full-text)

Related:

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Research: Circulating vitamin D concentration and risk of seven cancers

Research: Vitamin D and risk of total and site specific cancers

 

RCT: Vitamin D supplementation is not beneficial for the prevention of cardiovascular disease and cancer.

16 Jan, 2022 | 23:11h | UTC

Vitamin D supplementation and prevention of cardiovascular disease and cancer in the Finnish Vitamin D Trial-a randomized controlled trial – American Journal of Clinical Nutrition

News Release: Five years of high-dose vitamin D did not affect incidence of cardiovascular disease or cancer – University of Eastern Finland

Related:

Randomized Trial: Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Meta-Analysis: Vitamin D Not Effective for Cardiovascular Disease Prevention

Association between vitamin D supplementation and mortality: systematic review and meta-analysis – The BMJ

USPSTF Draft Statement: Insufficient evidence to recommend multivitamin supplements for the prevention of CVD or cancer. The statement also recommends against the use of beta-carotene (increases risk of CVD mortality and lung cancer) or vitamin E (clear evidence of no benefit)

Vitamin D, calcium, other vitamins, and supplements do not prevent cardiovascular diseases

Research: Circulating vitamin D concentration and risk of seven cancers

Research: Vitamin D and risk of total and site specific cancers

 

RCT: Ketamine induced remission in 46% of patients but was NOT non-inferior to electroconvulsive therapy for the treatment of hospitalized patients with unipolar depression.

16 Jan, 2022 | 23:01h | UTC

Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT) – International Journal of Neuropsychopharmacology

News Release: ECT more effective than ketamine in severe depression – Lund University

 

Commentary on Twitter

 

Perspective: Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age.

16 Jan, 2022 | 22:53h | UTC

Primary care providers should prescribe aspirin to prevent cardiovascular disease based on benefit−risk ratio, not age – Family Medicine and Community Health

Commentaries:

Researchers urge: ‘Prescribe aspirin based on benefit-to-risk not age’ – Florida Atlantic University

Preventive Aspirin Should Be Based on Benefit, Not Age – HealthDay

Related: USPSTF draft statement revises previous guidance and now recommends against initiating low-dose aspirin use for the primary prevention of CVD in adults aged 60 years or older.

 

Stay Updated in Your Specialty

Telegram Channels
Free

WhatsApp alerts 10-day free trial

No spam, just news.